संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. patients who have developed a severe reaction to allopurinol tablets should not be restarted on the drug.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg - loperamide hydrochloride capsules are indicated for the control and symptomatic   relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory   bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from   ileostomies. loperamide hydrochloride capsules are contraindicated in: - pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see warnings). - patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. - patients with abdominal pain in the absence of diarrhea. - patients with acute dysentery, which is characterized by blood in stools and high fever. - patients with acute ulcerative colitis. - patients with bacterial

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol tartrate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration, contraindications and warnings). metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol and related derivatives, or to

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or d

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: - for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; - the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; - the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: - aldosterone levels may be exceptionally high in this cond

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 60 mg - antihistamine temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: - runny nose - sneezing - itchy, watery eyes - itching of the nose or throat if you have kidney disease. your doctor should determine if you need a different dose. an allergic reaction to this product occurs. seek medical help right away.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - mafenide acetate (unii: rq6lp6z0wy) (mafenide - unii:58447s8p4l) - mafenide 85 mg in 1 g - sulfamylon cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. sulfamylon is contraindicated in patients who are hypersensitive to it. it is not known whether there is cross sensitivity to other sulfonamides.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - mafenide acetate (unii: rq6lp6z0wy) (mafenide - unii:58447s8p4l) - mafenide acetate 50 g - sulfamylon® for 5% topical solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds. sulfamylon® for 5% topical solution is contraindicated in patients who are hypersensitive to mafenide acetate. it is not known whether there is cross sensitivity to other sulfonamides.